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Abstract
Background: An estimated 14 % of the 1.2 million individuals living with HIV in the U.S. are unaware of their status.
Yet this modest proportion of individuals with undiagnosed HIV is linked to 44–66 % of all new infections. Thus
innovative intervention approaches are needed to seek out and test those with undiagnosed HIV, and link them to
HIV treatment with high retention, an approach referred to as “Seek, Test, Treat, and Retain” (STTR). The present
protocol describes a creative “hybrid” STTR approach that uses anonymous HIV testing followed by confidential care
linkage, focused on heterosexuals at high risk (HHR) for HIV, who do not test as frequently as, and are diagnosed
later, than other risk groups.
Methods/Design: This is a single-arm exploratory intervention efficacy trial. The study has two phases: one to
seek out and test HHR, and another to link those found infected to HIV treatment in a timely fashion, with high
retention. We will recruit African American/Black and Latino adult HHR who reside in urban locations with high
poverty and HIV prevalence. Participants will be recruited with respondent-driven sampling, a peer recruitment
method. The “Seek and Test” phase is comprised of a brief, convenient, single-session, anonymous HIV counseling and
testing session. The “Treat and Retain” component will engage those newly diagnosed with HIV into a confidential
research phase and use a set of procedures called care navigation to link them to HIV primary care. Participants will be
followed for 6 months with objective assessment of outcomes (using medical records and biomarkers).
Discussion: Undiagnosed HIV infection is a major public health problem. While anonymous HIV testing is an
important part of the HIV testing portfolio, it does not typically include linkage to care. The present study has potential
to produce an innovative, brief, cost-effective, and replicable STTR intervention, and thereby reduce racial/ethnic
disparities in HIV/AIDS.
Trial Registration: ClinicalTrials.gov, NCT02421159, Registered April 15, 2015.
Keywords: Anonymous HIV testing, Heterosexuals, Health status disparities, Undiagnosed HIV, African American,
Latino
* Correspondence: mg2890@nyu.edu
1Center for Drug Use and HIV Research (CDUHR), New York University
College of Nursing, 433 First Avenue, 6th floor, New York, 10010 NY, USA
Full list of author information is available at the end of the article
© 2015 Gwadz et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Gwadz et al. BMC Public Health  (2015) 15:1133 
DOI 10.1186/s12889-015-2451-5
Background
More than three decades into the domestic HIV epidemic,
over 55,000 individuals in the United States become in-
fected with HIV each year, concentrated mainly among
poor, stigmatized, and vulnerable populations [1]. African
American/Black and Latino individuals are greatly over-
represented in both incident and prevalent HIV cases [1]
and substance use is a major risk factor for both HIV
transmission and poor HIV health outcomes [2].
Of particular concern, an estimated 14 % of the 1.2
million individuals living with HIV in the United States
are unaware of their HIV status [3]. Yet this modest pro-
portion of individuals with undiagnosed HIV is linked to
an estimated 44–66 % of all new HIV infections annually
[4, 5], and uncovering this hidden group is an important
public health priority. African Americans/Black and La-
tinos remain undiagnosed longer than Whites [2] and
undiagnosed HIV is more common in males compared
to females, and among heterosexual males compared to
men who have sex with men (MSM) [2]. (Acronyms
used in this protocol description are defined in Table 1.)
In 2010, the National Institute on Drug Abuse (NIDA)
at the National Institutes of Health called for research
on new approaches to seek out persons with undiag-
nosed HIV, provide them with HIV counseling and test-
ing, and then link those found to be HIV infected into
medical care with high retention, which are referred to as
“Seek, Test, Treat, and Retain” (STTR) studies (e.g., RFA-
DA-11-001) [6]. The present protocol describes one such
study focused on uncovering undiagnosed HIV infection
among the population of heterosexuals at high risk (HHR)
for HIV infection, who comprise 27 % of new HIV infec-
tions, but who are under-studied compared to other risk
groups such as MSM and persons who inject drugs
(PWID) [7]. The study focuses in particular on African
American/Black and Latino HHR, who are concentrated
in high- poverty urban geographical areas with a high local
HIV prevalence, and who comprise the majority of HHR
[8, 9]. Indeed, the Centers for Disease Control and Pre-
vention (CDC) has called for research to test culturally ap-
propriate interventions to overcome barriers to HIV
testing and increase linkage to HIV care for heterosexuals
in high-risk urban areas [10], where a generalized epi-
demic can be said to exist [11, 12].
Barriers to HIV testing and timely engagement in HIV
care for HHR
African American/Black and Latino HHR experience bar-
riers to regular HIV testing, and subsequent engagement
in HIV care if found to be HIV-infected, at multiple levels
of influence. The present study conceptualizes these bar-
riers within the Theory of Triadic Influence [13]. The The-
ory of Triadic Influence is a social cognitive framework
that emphasizes three “streams of influence” on health be-
havior: the individual/attitudinal, the social, and the struc-
tural. Among HHR, barriers to testing at the individual
level of influence include lack of awareness of recom-
mended testing frequency, and low perceived risk of HIV
infection stemming from beliefs that HIV affects mainly
PWID and MSM [14, 15]. Concurrently, fear of HIV test-
ing and of a positive HIV test result are additional com-
mon individual-level barriers [16, 17], as is mistrust of
medical environments [16]. Substance use is common
among HHR and also serves as an impediment to HIV
testing and linkage to care [16, 18]. Moreover, the popula-
tion has other “competing priorities,” complicated by low
socioeconomic status, such as mental health problems
and unstable housing [14, 19]. At the social level of influ-
ence, the potential stigma of HIV testing and of a positive
test result serve as barriers to HIV testing [20]. Moreover,
peer norms regarding health care, including norms that
regular HIV testing is not necessary for HHR, may impede
testing [21]. At the structural level of influence, HHR
have less access to settings where high-quality HIV test-
ing is offered than their peers in the general underlying
population [22, 23]. Theoretically, barriers at these
three levels of influence interact to impede access to
HIV testing and reduce motivation to test among HHR.
Furthermore, this same set of barriers also impedes
linkage to and retention in HIV primary care among
HHR newly diagnosed with HIV [24–26]. The present
protocol describes a culturally targeted STTR interven-
tion strategy for HHR to reduce these barriers to HIV
testing and timely engagement in HIV care.
Table 1 Acronyms used
ACASI Audio Computer-Assisted Interviewing format
CDC Centers for Disease Control and Prevention
HHR Heterosexuals at high risk (for HIV)
HRA High-risk area
ICER Incremental cost-effectiveness ratios
MI Motivational Interviewing
MRF Medical Report Form
MSM Men who have sex with men
NHBS National HIV Behavioral Surveillance
NIDA National Institute on Drug Abuse
OR Odds Ratio
PWID Persons who inject drugs
RDS Respondent-driven sampling
RDS-ASTN Anonymous single-session testing with
navigation (using RDS)
RDS-CTTN Confidential two-session testing with
navigation (using RDS)
STTR Seek, Test, Treat and Retain
VBS Venue-based sampling
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Our research team’s studies of STTR approaches
We recently published a protocol describing a study of
two approaches for uncovering individuals with undiag-
nosed HIV infection [27]. One is a “Seek and Test” study
using venue-based sampling (VBS) as its recruitment
method. This approach provides confidential HIV coun-
seling and testing in a single session in randomly se-
lected public venues. The second approach is an STTR
study using respondent-driven sampling (RDS) to enroll
participants, followed by two intervention sessions (for
engagement and training in how to recruit peers in the
first session, and confidential HIV counseling and testing
using a rapid HIV test provided in the second session),
followed by care navigation to link those found HIV in-
fected to health care in a timely fashion [27]. (The activ-
ities that make up the care navigation approach are
described below.) RDS is a sampling methodology for
studying subpopulations that are hard to define, reach,
and/or engage. RDS is network-based method , similar
to traditional snowball sampling, but with the goal of
minimizing biases typically associated with those trad-
itional methods [26, 28]. In RDS, a modest number of
individuals are recruited directly by project staff (called
“initial seeds”), and then trained to recruit a small num-
ber of their peers into the study. These peers then enter
the study and peer recruitment continues until the sample
size goals are met [26, 29]. The RDS method has four es-
sential elements: tracking of recruitment chains; rationing
of recruitment (usually 2–5 peers each); information on
personal networks must be gathered (network size, re-
cruitment refusals); and recruiters and recruits must have
a pre-existing relationship [21]. We refer to this former
study as VBS and the latter study as RDS-CTTN (“Confi-
dential Two-session Testing with Navigation”). These two
STTR studies are located in central Brooklyn, a location
within New York City with high rates of poverty and
highly prevalent HIV infection among heterosexuals,
where African American/Black and Latino populations
predominate [27]. In the present protocol we describe
an innovative third STTR approach being evaluated in
the same high-risk area in central Brooklyn, focused on
the same vulnerable population of HHR. In contrast to
the RDS-CTTN and VBS approaches which are provid-
ing confidential HIV testing, this “hybrid” approach be-
gins with anonymous HIV testing in its “Seek and Test”
phase, and then delivers intervention components to
engage those found to be HIV infected in to a confiden-
tial “Treat and Retain” phase in order to link them to
HIV care in a timely fashion, using care navigation.
The pros and cons of anonymous testing
Anonymous HIV testing remains a critical part of the HIV
testing portfolio. Anonymous testing is available in state
and local health departments, in cases of occupational
exposure, through home test/self-test technologies, and re-
search studies including the National HIV Behavioral Sur-
veillance (NHBS) system [30, 31]. There is some evidence
to suggest individuals who test anonymously do so earlier in
the course of their HIV disease than those who engage in
confidential testing [32]. Additionally, anonymous testing
may be useful for and/or preferred by individuals from mar-
ginalized populations [33]. As Kegeles and colleagues have
found, many who seek anonymous HIV testing would avoid
it under other circumstances, and anonymous testing may
be preferred among those who suspect they are infected
[34], and those who fear stigma and discrimination [35].
Moreover, in addition to being anonymous, the intervention
described in the present protocol is designed to be brief and
easy to access, with HIV counseling and testing conducted
in a single efficient session. Thus, we hypothesize a brief,
convenient, single-session, anonymous HIV testing effort
may appeal to and engage HHR who face barriers to confi-
dential and/or more labor intensive HIV testing.
Yet while anonymous testing may be an effective and/
or efficient strategy in the ‘seek’ phase of STTR, it does
not address the vital step of linkage to HIV care for
those found to be HIV infected. In fact, although an-
onymous testing tends to yield individuals earlier in
their HIV disease, those who test anonymously are
more likely to experience delays entering care, because
anonymous testing sites and programs do not typically
have the resources to engage individuals into linkage pro-
grams and generally are not co-located with medical care
[36, 37]. For example, in a study of characteristics of the
HIV testing encounter and linkage to care, Reed [38]
found that 36 % of those testing anonymously did not
enter care within three months of diagnosis, compared
with 26 % of those testing confidentially [38]. Similar to
the RDS-CTTN study, participants in the present protocol
are recruited using RDS, in order to access a largely vul-
nerable and hidden population of HHR, and we refer to
the intervention described in this protocol as RDS-ASTN
(“Anonymous Single-Session Testing with Navigation”).
Study aims
This study has aims related to the Seek and Test as well
as Treat and Retain project phases. In the Seek and Test
phase, aims include estimating the proportion of HHR
completing HIV testing, and the proportion found with
previously diagnosed and newly diagnosed HIV infec-
tion. In the Treat and Retain Phase, aims include the
feasibility of enrolling those newly diagnosed with HIV
infection into a confidential research phase, as well as
estimating the proportion successfully linked to care
within three months. In both phases, participants in this
protocol will be compared with participants recruited
using the two other approaches to STTR (VBS and
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RDS-CTTN) described above and presented in detail
elsewhere [27].
Methods/Design
Study setting in central Brooklyn
Modeled on procedures developed for the NHBS system,
the study will be conducted in a contiguous set of zip
codes with the highest HIV prevalence and poverty rates
in Brooklyn, NY, one of the five boroughs that make up
New York City. We refer to this location as the “high-
risk area” (HRA). The HRA is comprised of both a core
HRA made up of seven contiguous zip codes with the
highest rates of heterosexual HIV infection and poverty
(the top 25 % of rank ordered zip codes), surrounded by
an area made up of the second highest quartile of zip
codes with respect to HIV prevalence and poverty (an
additional 12 zip codes) (See Fig. 1). The procedures to
select the HRA are described elsewhere [27]. In order to
compare findings among the present study of RDS-
ASTN and the VBS and RDS-CTTN studies, all three
will be conducted in this same HRA. However, given the
three studies’ aims to evaluate strategies to identify un-
diagnosed HIV infection, the present protocol is
designed to avoid enrolling participants also enrolled in
RDS-CTTN and thereby to tap into a different set of
networks for RDS-ASTN. This is feasible because the
HRA covers a large geographical area and the total
population of the HRA is approximately 524,298 [39],
mostly HHRs (Brooklyn’s total population is more than
2,600,000 [40]). Thus the present protocol includes proce-
dures to reduce or eliminate cross-enrollment of partici-
pants who participated in RDS-CTTN into the present
study, as we describe below. Those enrolled in VBS can
participate in the present study, because VBS does not rely
on networks for recruitment and VBS participants’ re-
cruitment into RDS-ASTN via networks is consistent with
the study’s larger goals, which include allowing network
recruitment to proceed with relatively few restrictions.
Design
BCU is a single-arm exploratory intervention efficacy trial
conducted in two parts. As noted above, participants are
recruited using RDS. In the Seek and Test phase, partici-
pants recruited through peers present to the study, pro-
vide verbal informed consent, are screened, enrolled, and
provided with anonymous HIV counseling and testing in a
Fig. 1 Core High-risk Area (HRA; in light grey) and surrounding larger HRA, in the borough of Brooklyn
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brief, single session, where a blood specimen is obtained
for laboratory testing for HIV infection and results are
provided 1-2 weeks later. In the Treat and Retain phase, a
confidential research phase, those found to be HIV-
infected in the Seek and Test phase are asked to give their
names, provide signed informed consent, and engage in
care navigation lasting 3–6 months to link them to HIV
primary care in a timely fashion. Participants who present
to the study with previous HIV diagnoses may enroll in
the study, but do not receive HIV testing, as described
below. However, they do have the opportunity to recruit
peers. The study uses principles of behavioral economics
and Motivational Interviewing (MI) to engage participants
and increase their motivation to return for test results and
enroll in the Treat and Retain phase if found HIV infected,
described below. The protocol is registered with clinical-
trials.gov (NCT02421159) and the overall study design is
presented in Fig. 2.
Ethics statement
Study activities are approved by the Institutional Review
Board at the New York University School of Medicine
(OHRP #FWA00004952).
Outcomes
The primary outcome of the Seek and Test phase is the
relative yield (that is, proportion of newly identified
HIV infections) of the RDS-ASTN intervention. We
will assess the proportion of those newly diagnosed that
engages in activities of the Treat and Retain phase (i.e.,
the feasibility of switching from an anonymous to a
confidential phase). The primary endpoints for the
Treat and Retain phase are the proportion linked to
HIV primary care within three months (i.e., attending a
care appointment and receiving CD4 and viral load
tests) and time to the HIV care appointment. We will
assess the acceptability and safety of the intervention
components, as well as their cost-effectiveness. Because
we examine many of these same endpoints in the other
two components of the STTR study (VBS, RDS-CTTN),
we can compare findings across the three STTR strategies.
Study population and sampling considerations
An estimated 750 participants will be recruited by
peers and screened, and 500 of these will be enrolled.
An estimated 45 % of the sample will be female. An es-
timated 60 % of the sample will be African American/Black,
35 % Latino/Hispanic, and 5 % White/non-Hispanic. We
estimate that > 50 % of the sample will be substance users.
Given estimates of HIV incidence and prevalence in the
local National Behavioral Surveillance System studies [41],
we expect to identify 65 participants with HIV infection, 40
(8 %) newly diagnosed and 25 previously diagnosed with
HIV.
Hypotheses
The study will explore the following hypotheses: compared
with VBS and RDS-CTTN, and controlling for potential
differences on key socio-demographic characteristics
across the samples, RDS-ASTN participants will have less
Fig. 2 Primary activities conducted in the two-phase study
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HIV testing experience. Further, controlling for potential
differences on key socio-demographic characteristics
across the samples, RDS-ASTN will yield substantially
higher rates of previously undiagnosed HIV compared
with VBS and modestly higher rates compared to RDS-
CTTN, although the RDS-ASTN intervention is less labor
intensive than RDS-CTTN. This is because the brief and
anonymous nature of the RDS-ASTN intervention may
appeal to highly vulnerable individuals with multiple bar-
riers to HIV testing. Further, we hypothesize that most
participants (> 70 %) found to be HIV-infected in the
RDS-ASTN intervention will engage in the Treat and Re-
tain phase of the study, grounded in the efficacy of the MI
approach combined with compensation based on behav-
ioral economics principles to foster engagement. Last, we
hypothesize that most participants in the Treat and Retain
part (> 70 %), all of whom will be HIV infected, will be
linked to care within 3 months, based on past studies of
care navigation with similar populations [42, 43].
Eligibility criteria
The study’s eligibility criteria are:
 18–60 years of age
 sexually active (vaginal sex or anal sex) with at least one
partner of the opposite sex within the previous year
 reside in the seven zip core central Brooklyn
HRA (initial seeds only; peers may reside in
the larger 19 zip code HRA)
 comprehend English or Spanish
 HIV negative or unknown HIV status
(initial seeds only; peers may be ‘known positives’)
 willing to try to recruit peers
 not actively psychotic based on valid screening
instrument
 not enrolled already in RDS-ASTN or in
RDS-CTTN
Monolingual Spanish-speaking individuals are eligible for
enrollment. All consent forms, recruitment, retention, as-
sessment, and intervention materials will be translated into
Spanish using the back-translation method [44]. Although
the present study focuses on African American/Black and
Latino/Hispanic populations, there is no race/ethnicity
eligibility criterion to allow RDS recruitment chains to
evolve with minimal restrictions. However, it is anticipated
that > 95 % of participants will be African American/Black
or Latino/Hispanic based on local population demograph-
ics and typical RDS recruitment patterns where peers tend
to recruit racially/ethnically similar peers [45, 46].
Individuals with previously diagnosed HIV infection
Participants who report they have previously been diag-
nosed as HIV infected during the screening interview,
called “known positives,” may be enrolled in the study
and may recruit peers. Indeed, HIV infected individuals
may be an important link to those with undiagnosed
HIV infection. HIV status will be confirmed with medical
documentation by study staff by viewing one of the fol-
lowing: HIV diagnosis letter from a testing site; documen-
tation of AIDS Drug Assistance Program coverage (a
Federal program to provide HIV medications); a copy of
the most recent HIV lab results or medical record includ-
ing HIV diagnosis from a medical facility; current or re-
cent antiretroviral therapy prescription or medication
bottles; a signed and dated doctor’s note; or an M11Q, the
New York State certification of an individual’s AIDS or
HIV-symptomatic diagnosis. The type of documenta-
tion provided will be noted in a participant log. To pre-
serve anonymity, the documentation will not be copied
or retained by the study and no names or identifying in-
formation will be recorded. We have used these proce-
dures to document HIV status in past studies [27, 46].
Study activities for those with known HIV infection are
described below. In the next section we describe proce-
dures for those who enter the study with an HIV-negative
or unknown status.
Seek and test phase (Anonymous)
Study elements to foster participation, engagement,
and retention
The study includes a number of components designed
to build trust, engagement, and relationships, and to
thereby encourage participation in study activities with
high retention, while fostering a high quality experience
for participants. First, the anonymous nature of the
Seek and Test phase is designed to foster engagement.
Second, study activities, including the intervention ses-
sions, are grounded in the MI approach. MI is a flexible,
collaborative counseling method that actively engages, fo-
cuses, and guides participants, without judgment or pres-
sure, in order to elicit and strengthen durable, high quality
intrinsic motivation for behavior change [47]. Consistent
with this approach, participants’ choices and autonomy
are respected, including if they decline to participate in
study activities. Moreover, we will select study staff from
diverse socioeconomic and racial/ethnic backgrounds,
who enjoy working with substance-using and other vul-
nerable populations, and are knowledgeable about the
concerns substance users and vulnerable populations ex-
perience, and who are expert in HIV testing and HIV care
navigation. The study field site will be conveniently lo-
cated in the HRA. Peer recruitment is another means of
fostering engagement, because peers have credibility and
peer recruitment is a type of endorsement of the project
[26, 46, 48]. Last, as we describe below, compensation is
structured using principals of behavioral economics to
boost motivation to return for test results.
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Recruitment
Initial seeds who start recruitment chains (N = 2–20 ini-
tial seeds depending on recruitment rates) are recruited
by study staff from outdoor and public venues in the
neighborhoods located in the HRA; peers recruited by
study participants will present to the study field site with
a coded recruitment coupon that links the recruiter to
the recruit, to track recruitment chains and compensate
the recruiter.
Consent
As described below, participants provide informed con-
sent before engaging in study activities. In keeping with
the anonymous nature of the “Seek and Test” study
phase, verbal informed consent will be obtained. Partici-
pants entering the “Treat and Retain” study phase will
provide signed informed consent.
Screening for eligibility for the Seek and Test Phase
Verbal consent for a brief screening interview is ob-
tained. Study staff will review the informed consent
form for screening with potential participants and
obtain their verbal informed consent for a brief, com-
puterized screening interview to determine eligibility.
Study staff will use a handheld or laptop computer to
document the participant’s informed consent and then
conduct the screening interview, which covers the eligi-
bility criteria noted above. Individuals are given a copy
of the screening informed consent form for their re-
cords. No names or identifying information will be col-
lected from study participants; only unique identifiers
will be used. Participants are compensated $15 for their
time for this screening interview. Additionally, funds for
local round-trip public transportation for all in-person en-
counters (assessments, sessions, navigation) are provided.
Enrollment in the Seek and Test phase
Individuals who meet the eligibility criteria and are
interested in participating in the Seek and Test phase
will provide verbal informed consent to enroll into this
phase, documented using a handheld/laptop computer.
The consent form explains that this phase of the study is
anonymous, and reviews study activities including a
computerized baseline interview; an HIV pre-test coun-
seling session; blood draw for HIV testing; use of blood
samples for clinical lab tests (viral load, CD4), if found
to be HIV infected; and a post-test counseling session to
receive test results. Compensation levels are explained at
this time. Individuals are given a copy of the informed
consent form for the Seek & Test phase, and told that if
they are found HIV-infected, the project will provide
support to them as they adjust to their diagnosis. Partici-
pants are informed that, with their consent, if they are
found to be HIV-positive, blood specimens will be tested
for HIV viral load levels for research purposes without
names, and that unused blood will be discarded. If their
HIV test results are negative, all of their remaining blood
specimens will be discarded. Individuals must agree to
the baseline interview and counseling session to enroll
in the study, which take place on the same day, but can
decline the other components and continue in the study.
Baseline interview
Participants then engage in a brief baseline interview
(< 30 min) conducted in audio computer-assisted self-
interviewing (ACASI) format. The assessment battery is
comprised of a set of measures used in the National In-
stitute on Drug Abuse (NIDA) funded STTR projects
for vulnerable populations, assessing domains such as
socio-demographic characteristics, HIV testing history,
substance use frequency, substance use problems, and
sexual partners [6, 49]. Participants are compensated
$20 for their time for this assessment.
Counseling intervention session and HIV testing
Individuals then complete a private one-on-one inter-
vention/ counseling session led by a study staff member,
lasting approximately 30–40 min, guided by the MI ap-
proach. The underlying goal of the first session is to en-
gage participants into the study, build trust and
relationships, and foster motivation to engage in study
activities. The session consists of a series of brief exer-
cises. First, participants are introduced to the study. The
study rationale is described, and respect for participants’
choices and decisions throughout is emphasized. This
includes the core message that if the participant tests
positive for HIV, the study staff will help them get the
high quality care they need, and if the participant tests
HIV-negative, the study will provide them with referrals
to help them stay that way. Second, the distinction be-
tween the anonymous Seek & Test study phase and the
confidential Treat and Retain phase is briefly described,
again with an emphasis on participants’ choices and au-
tonomy. Third, HIV pre-test counseling is provided,
consisting of a review of elements either required or rec-
ommended by the CDC and local Department of Health,
such as a review of the nature of HIV and HIV transmis-
sion and risk reduction, review of the benefits of HIV
testing and early treatment, explanation that HIV testing
is voluntary, explanation of anonymous and confidential
testing, and a review of confidentiality and discrimin-
ation protections and partner notification services. Next,
participants receive a brief training on how to recruit
peers for the study, and are encouraged to do so. This
includes: who to recruit, how and when to approach
peers, and how to refer peers to the project using a
coded recruitment coupon. Then, a highly trained, expe-
rienced phlebotomist draws a blood specimen, which is
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sent to a laboratory for HIV testing, and a handout de-
scribing next steps in the study is reviewed, namely, the
participant is asked to return to the project in approxi-
mately 7–14 days to collect compensation for peer re-
cruitment (if any) and meet with the interventionist for
post-test counseling and test results.
The blood specimen is transported using packaging
mandated in the Federal Code of Regulations, CDC 42
CRF Part 72 and tested with the 4th generation Alere
assay (HIV-1/O/2 Antigen/Antibody Preliminary Test
with Cascade Reflex to Supplementary Testing). The 4th
generation HIV test allows diagnosis of the earlier, acute
phase (recent) of HIV infection, prior to the emergence
of antibodies, effectively reducing the period after initial
infection and before the detection of infection based on
formation of detectable antibodies. The local Depart-
ment of Health recommends the use of the 4th gener-
ation HIV testing algorithm [50]. All work with human
fluids is conducted at Biosafety Level 2. At this time,
blood specimens are processed and stored for future
HIV viral load testing if the participant tests positive for
HIV. (It is not possible to store specimens for CD4 test-
ing, so a second blood draw is conducted as appropriate
in the second session.) Participants are compensated $15
for their time for this session, and $25 for the blood
draw for HIV and viral load testing. They can complete
the session and decline the blood draw and HIV testing.
Building motivation to return for test results
The study includes a number of techniques to boost the
proportion of participants who return for test results,
which are necessary given that participants cannot be
contacted or reminded about future activities. Drawing
on work by Volpp and colleagues [51] that shows people
are motivated by the experience of past rewards and the
prospect of future rewards, participants in the first inter-
vention session will enter a lottery with a good probabil-
ity of winning a modest prize, namely, a 1 in 5 chance of
winning $25, and a high probability of winning the
smaller prize; that is, a 4 in 5 chance of winning $10 (a
"high-odds, low-dollar" lottery) [51]. In the second ses-
sion, participants will have a chance to participate in a
"low-odds, high-dollar" lottery, with a 1 in 38 chance of
winning a $50 prize, with the remainder receiving a low-
dollar prize ($15). Second, participants are asked to ad-
dress an appointment reminder card to themselves at
the conclusion of the first intervention session, and place
it themselves in a locked box, the contents of which are
not visible to staff. Study staff will empty the cards from
the lock box into a mailbox at the end of each day, with-
out seeing any names or addresses. These retention
methods will be explained in the consent form of the
Seek and Test part. The study does not involve decep-
tion in any phase; all procedures are transparent.
Peer recruitment period
After the intervention session, participants then enter
the “peer recruitment period” of approximately 7–14
days during which they have the opportunity to recruit
2–6 peers to the study (depending on study recruitment
patterns) using coded recruitment coupons that link the
recruiter’s unique identification number to the recruit.
When 3 or more coupons are distributed, at least one of
the coupons is designated for females only, to boost the
proportion of women in the study. Participants follow a
recruitment script that instructs them to recruit individ-
uals aged 18 – 60 years old; who they know by name or
face, and who live in the larger HRA. Peers will be
screened for eligibility, as described above. Recruiters re-
ceive $5 for each peer who presents for screening, plus a
bonus of $10 for each eligible peer, for a total of $15 per
eligible peer.
Procedures to prevent duplicate enrollments
To prevent participants from enrolling in the present
study (RDS-ASTN), and also in RDS-CTTN, the present
has its own name (“Brooklyn Community United,” or
BCU) and recruitment coupons have a different color
than those used in RDS-CTTN. The screening interview
assesses whether participants are enrolled in the RDS-
CTTN study, and the participant’s unique identifier is
checked against a master database. Participants are in-
formed during the consent process they may be with-
drawn from the study if they have been previously
enrolled in RDS-CTTN. Initial seeds to start peer re-
cruitment will be recruited from the same HRA as the
RDS-CTTN participants, but from the zip code with the
fewest number of RDS-CTTN participants, as a means
of tapping into network recruitment chains of individ-
uals with no exposure to RDS-CTTN. Although we may
not be able to eliminate duplicate enrollments, these
procedures will greatly reduce their occurrence.
Treat and Retain Phase (Confidential)
Post-test counseling session for all participants
Participants return for their HIV test results approxi-
mately two weeks after the first session, and if found to
be HIV infected, are presented with the opportunity to
enroll in the Treat and Retain phase to receive support
as they adapt to the new diagnosis, and link to HIV care
in a timely fashion. They also receive compensation for
peer recruitment at this time, which may encourage at-
tendance at this appointment. (They can receive com-
pensation for peer recruitment and decline to participate
in the second session, however.) The session begins with
elements either required or recommended by the CDC
and local Department of Health for post-test HIV coun-
seling. For participants whose test results are negative,
the interventionist will address personal HIV risk/harm
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reduction; note CDC recommendations for annual test-
ing; and will provide verbal instructions or a written re-
ferral directory for community-based HIV prevention
services and other services (mental health care, sub-
stance use, housing). This session is brief (< 10 min) and
will be the last study activity for HIV-negative study par-
ticipants. Participants are compensated $15 for their
time for this session.
For those who are found newly infected with HIV, the
session is designed to provide post-test counseling. In
addition, it will foster engagement into the Treat and
Retain phase through demonstrated expertise of the
interventionist with respect to HIV and HIV primary
care, and continued use of the MI approach to build
motivation to accept care navigation and support. This
session will last approximately 60 min. Regarding post-
test counseling, the interventionist will: provide the
positive test result, and elicit and discuss reactions to
the diagnosis, with a discussion of typical next steps for
newly diagnosed individuals including adjustment, lim-
ited disclosure, HIV primary care, and reducing sexual
and injection-related risk behavior. The interventionist
will provide psychological support, ensure that the cli-
ent has accurate information about steps necessary to
prevent transmission; discuss with the participant
whom to notify of his/her positive test result; offer as-
sistance with short-term planning to cope with new
diagnosis and emphasize the importance of HIV care.
As a central aim of this study is to facilitate transition
to the confidential Treat and Retain phase, which in-
volves relinquishing anonymity, a portion of the session
will be devoted to explaining this phase. To foster en-
gagement, culturally targeted core messages will in-
clude: framing the problem of delayed linkage to care
as a community issue (highlighting both racial/ethnic
disparities in linkage to care and HIV outcomes, and
progress made in linkage among populations of color);
discussing multi-level barriers that individuals experi-
ence to HIV care, related to gender, substance use, low
socio-economic status, and/or race/ethnicity; explaining
what “confidential” means, including laws regarding
reporting of names of newly diagnosed individuals to
the local Department of Health (which is mandatory in
our jurisdiction); providing handouts with activities and
compensation; reviewing a menu of options and evok-
ing benefits of each; and determining if the participant
wishes to enroll in the Treat and Retain phase. All par-
ticipants have the opportunity to engage in the lottery
activity at this point.
Finally, we will make an HIV care appointment for the
participant regardless of whether or not he/she enrolls
in the Treat and Retain phase, consistent with local pub-
lic health law. Participants who have not given their full
name to the study can be put on the phone directly with
the HIV care site and provide that information directly
to the facility.
Enrollment into the Treat & Retain Phase
Participants who are interested in enrolling in the Treat
& Retain phase will next enter that phase of the study,
beginning with signed informed consent and completing
a locator form. Participants who are unsure whether
they wish to enroll have a “grace period” of approxi-
mately three weeks to decide. They can contact the
study to schedule an enrollment visit within that period.
Compensation of $15 is provided for the second session.
Care navigation
Care navigation is a flexible and individualized interven-
tion approach to reduce disparities in care for low in-
come or marginalized populations [52, 53]. In practice,
care navigation identifies and resolves the organizational,
social, and individual barriers patients may experience to
accessing services [54]. We will provide care navigation
to newly diagnosed HIV-infected participants over a
three- to six-month period, depending on the partici-
pant’s needs. During navigation, participants will be
aided to identify and overcome barriers that they may
encounter at various steps during the course of their
linkage to HIV care. Navigation will consist of face-to-
face meetings and phone contacts to provide partici-
pants with support, assistance making decisions about
disclosing their HIV status, referrals, coordination of
care, accompaniment to medical appointments, and as-
sistance to get other necessary services or care. Only a lim-
ited number of face-to-face meetings will be compensated
($10, up to 5 compensated meetings in the first month) so
as to not artificially increase navigation “dose.” Participants
will be encouraged to contact the study outside of sched-
uled care navigation meetings/contacts for additional help
or support, as needed. Duration and content of care
navigation contacts are based on individual participant
needs and will vary across participants, and will be
logged to document their duration and content. We es-
timate that > 70 % of participants will be engaged in
care by the end of three months. Those who are not en-
gaged have the option of extending the care navigation
period for an additional 3 months, for a total of
6 months of care navigation.
Additional recruitment coupons
Individuals who test HIV-positive have the opportunity to
recruit three additional peers during the care navigation
phase, a type of network-based case finding [55, 56]. They
will be encouraged to recruit their sexual and injection
drug using partners, if they have not done so already.
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Medical Report Form and blood draw
At the end of the 6-month Treat and Retain phase, we
will ask participants to have a Medical Report Form
(MRF) completed by their HIV care provider. The
Medical Report Form will contain health care appoint-
ment data abstracted from their medical chart, and will
be signed by a health professional at the facility where
the participant receives care. Participants can request that
the form be filled out and return it to us, for which they
will receive compensation ($25). Alternately, participants
can request for us to contact the provider directly to ob-
tain the data either over the phone, by secure fax or in
person. Further, study staff will obtain a second set of
blood specimens for CD4 and HIV viral load testing at the
end of 6 months, and participants will be compensated
$25 for this blood draw.
Follow-up interview
At the end of the 6-month care navigation period, par-
ticipants will be asked to participate in a brief follow-up
interview assessing the health, relationship, and sub-
stance use indices assessed in the baseline interview, but
focused on the past 6 months, as well as safety (social
harms) and intervention acceptability. The follow-up
interview will be conducted using the ACASI format
($30 compensation).
Procedures for participants who are “known positives”
(not shown on Fig. 2)
Individuals who report being HIV-infected during the
screening interview and who meet the study’s eligibility
criteria will provide verbal informed consent for and be
enrolled in a track of the Seek and Test phase of the
study. These participants will be asked to provide med-
ical documentation of their HIV-positive status (which
will be viewed but not retained); they will engage in a
baseline interview that includes questions on their HIV
history (e.g., date of first diagnosis with HIV), and re-
ceive a brief intervention session to orient them to the
study and train them how to recruit peers. They will not
be tested for HIV or receive other lab tests. Individuals
who cannot provide medical documentation of their
HIV-status will be enrolled in the main Seek and Test
phase (described above), and offered participation in all
of those activities. These HIV-infected participants who
are not well engaged in care by DHHS definition [57]
will be given the opportunity to enroll in the Treat and
Retain phase of the study, for which they will provide
signed informed consent. They will be asked to complete
a Medical Report Form at the beginning and end of the
Treat & Retain phase and will be provided with care
navigation over three months. Compensation will be
provided at the rates described above.
Analysis plan
First, we will compare the yield of RDS-ASTN with the
two other STTR strategies we described in a separate
protocol, RDS-CTTN and VBS [27], with respect to newly
diagnosed HIV infection. We will examine differences in
demographic characteristics between VBS, RDS-CTTN
and RDS-ASTN participants and adjust for these when
comparing STTR approaches. Logistic regression will be
used to compare the three STTR strategies on yield of
newly diagnosed HIV infection. Covariates will include
prior HIV testing.
Second, we will explore the feasibility of engaging
RDS-ASTN participants who test HIV-positive into a
confidential Treat and Retain study phase. Key indica-
tors of feasibility will include the percentage of partici-
pants with HIV infection who accept the transition from
the anonymous testing phase to the confidential Treat
and Retain phase; and rates of engagement in Treat and
Retain phase study activities. We also will explore the
efficacy of the Treat and Retain components in terms of
time to an HIV clinic appointment among newly identi-
fied HIV-infected HHR. We will describe the occur-
rence and timing of a first HIV clinic appointment and
whether viral load and CD4 results were obtained. Cox
proportional hazards regression will be used to compare
STTR strategies (RDS-CTTN and RDS-ASTN) on the oc-
currence and timing of first HIV clinic appointment.
Third, we will project the clinical impact, costs, and
cost-effectiveness of RDS-ASTN for identifying HHR,
and linking them to and retaining them in HIV-related
medical care. Incremental cost-effectiveness ratios (ICER)
will be presented in terms of costs per HIV infection pre-
vented and used to compare STTR strategies. We will
estimate the costs and effectiveness outcomes for ICERs
with projections from a mathematical model of HIV infec-
tions prevented, based on reductions in HIV risk behavior
[58, 59] and viral load suppression associated with treat-
ment [60, 61]. For outcomes not directly observed in
participants recruited by RDS-ASTN, we will assume
these are the same as for the RDS-CTTN intervention
group; that is, an RDS-ASTN participant linked to care
and retained for three months has the same probabil-
ities of ART initiation and viral load suppression as an
RDS-CTTN participant. The time horizon for our ana-
lysis is lifetime.
Finally, generalized linear models will be used to
compare the socio-demographic, substance use, health,
and HIV testing characteristics of those enrolled by
RDS-ASTN with those in RDS-CTTN and VBS. This
analysis will determine whether there are important dif-
ferences in risk behavior and HIV testing history among
these study groups, which may indicate differential ef-
fectiveness in reaching higher risk heterosexuals and
those who have not tested or have tested infrequently.
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Power analysis
The study is powered to detect a difference in Seek and
Test approaches between RDS-ASTN and VBS of odds
ratio (OR) OR = 2.92 and between RDS-ASTN and RDS-
CTTN of OR = 1.71, both with 80 % power (α = .05).
Power will be approximately 80 % to detect a small
effect size (d = .19) when comparing socio-demographic,
substance use, health, and HIV testing characteristics
across STTR approaches.
Limitations
The proposed study lacks a control condition that is
similar to the planned RDS-ASTN strategy but which
does not offer care navigation for those with HIV infec-
tion, as all HIV-infected participants will receive care
navigation. We considered randomly assigning seed par-
ticipants and their recruits to RDS-ASTN with and with-
out navigation to care, but because we are primarily
concerned with comparing the yield of newly diagnosed
infections across STTR strategies, we chose to include
the care navigation intervention for all ASTN partici-
pants. Moreover, a condition with brief, single-session an-
onymous testing and without care navigation may not
meet the standard of equipoise. Another limitation is the
brevity of follow-up; however, it will allow us to obtain
what we consider to be the two most important outcomes
needed to determine the feasibility and potential of this
STTR strategy: engagement in the confidential Treat and
Retain phase, and linkage to a first HIV clinic appoint-
ment. Last, the two Seek and Test approaches in the main
study and the novel approach to be examined in the
present study all compensate participants for study activ-
ities. Although compensation is similar across groups, the
yield in all groups may be higher than what could be
achieved without compensation for these activities.
Generalizability
In this study, reproducibility is more important than
generalizability. Although there are imperfect methods
for weighting RDS data to obtain representative samples,
this study does not seek to draw inferences based on
representativeness. Rather, the methods we propose to
recruit a population of HHR with excess rates of undiag-
nosed HIV should be reproducible, that is, application of
the same methodology in other settings should also re-
cruit a high-risk sample. This has been demonstrated to
some degree in NHBS. When the sample was restricted
to individuals living in urban HRAs where, as is charac-
teristic of all New York City HRAs, > 20 % of residents
lived below the poverty line, and HIV prevalence was 2.1
% - a rate that also meets the definition of a generalized
HIV epidemic [10]. Thus, evidence exists to support the
likelihood that the recruitment and intervention method
shown to yield the largest proportion of HIV-positive
HHR, and for which subsequent timely linkage to care is
reasonably successful, could produce similar results in
other impoverished urban settings.
Discussion
The present study seeks to examine an innovative anonym-
ous method to uncover undiagnosed HIV infection in an
understudied population: heterosexuals at high risk for
HIV. Further, it tests components to link those with HIV
infection to HIV primary care with high retention, both
newly diagnosed and those with previous HIV diagnoses.
Results can guide the addition of anonymous testing with
effective care linkage to the currently available portfolio of
STTR strategies, broadening the scope of testing and care
linkage to unknown HIV infected individuals for whom
confidential testing is not acceptable, and who may other-
wise never be linked to care. Study results will provide
guidance on the most efficient and cost-effective means of
uncovering this largely hidden and vulnerable population.
The ultimate aim of the present study is to provide an effi-
cient, cost effective, reproducible, and scalable sampling
method and intervention approach to address the critical
public health problem of undiagnosed HIV infection and
delays in engagement in HIV care among HHR. This proto-
col provides background for other investigators interested
in researching this population, which is challenging to de-
fine, reach, and engage. We hope to be able to delineate
characteristics (demographic, attitudinal, experiential) of
those who are averse to confidential testing, but willing to
engage in anonymous testing with subsequent care linkage;
these findings can inform targeted anonymous testing ef-
forts which could potentially have a significant impact on
the HIV burden in affected communities.
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